Megan G. Hofmeister
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Megan G. Hofmeister has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Eyasu H. Teshale
6 shared publicationsNeil Gupta
Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta Georgia USA
6 shared publicationsPhilip R. Spradling
Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta Georgia USA
5 shared publicationsCole Burkholder
Michigan Department of Health and Human Services
4 shared publicationsJim Collins
Michigan Department of Health and Human Services
4 shared publicationsShannon McBee
West Virginia Department of Health and Human Resources
4 shared publications
Latest Publications
- 24 January 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (2) , e70137
Epidemiology and Control of Widespread Community Hepatitis A Outbreaks in 37 U.S. States, 2016–2023
During 2016–2023, 37 U.S. states experienced hepatitis A outbreaks associated with person‐to‐person transmission. We sought to describe the epidemiology of the outbreaks and characterise outbreak response efforts over time. We analysed outbreak databases from 37 states, survey responses from 33 states, and hepatitis A case reports from the National Notifiable Diseases Surveillance System for all 50 states and Washington, DC, during August 1, 2016–December 31, 2023. Among 44,930 reported outbreak‐associated cases, most occurred among males (62%), non‐Hispanic White persons (65%), and those aged 30–49 years (54%); 62% were hospitalised and 1% died. Commonly reported risk factors for HAV infection were drug use (53%) and homelessness or unstable housing (14%). Sixty‐seven percent of adults had a documented indication for hepatitis A vaccination. In late 2017, CDC stood up a national incident management system to coordinate communication between outbreak‐affected states, facilitate vaccine delivery, and provide technical assistance. States with available data reported administering more than 5.3 million adult hepatitis A vaccines collectively; most states administered vaccines in correctional facilities, local health departments and homeless shelters. Outbreak‐associated cases peaked in 2019 and then declined annually. As outbreak response capacity scaled up nationwide, states with later outbreak start dates tended to experience smaller outbreaks than those with earlier start dates. Unprecedented hepatitis A outbreaks were controlled by a robust vaccine response in 37 states. Continued vigilance and providing access to vaccination for recommended populations will be critical to preventing similar outbreaks in the future.
- 24 January 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (2) , e70137
Epidemiology and Control of Widespread Community Hepatitis A Outbreaks in 37 U.S. States, 2016–2023
During 2016–2023, 37 U.S. states experienced hepatitis A outbreaks associated with person‐to‐person transmission. We sought to describe the epidemiology of the outbreaks and characterise outbreak response efforts over time. We analysed outbreak databases from 37 states, survey responses from 33 states, and hepatitis A case reports from the National Notifiable Diseases Surveillance System for all 50 states and Washington, DC, during August 1, 2016–December 31, 2023. Among 44,930 reported outbreak‐associated cases, most occurred among males (62%), non‐Hispanic White persons (65%), and those aged 30–49 years (54%); 62% were hospitalised and 1% died. Commonly reported risk factors for HAV infection were drug use (53%) and homelessness or unstable housing (14%). Sixty‐seven percent of adults had a documented indication for hepatitis A vaccination. In late 2017, CDC stood up a national incident management system to coordinate communication between outbreak‐affected states, facilitate vaccine delivery, and provide technical assistance. States with available data reported administering more than 5.3 million adult hepatitis A vaccines collectively; most states administered vaccines in correctional facilities, local health departments and homeless shelters. Outbreak‐associated cases peaked in 2019 and then declined annually. As outbreak response capacity scaled up nationwide, states with later outbreak start dates tended to experience smaller outbreaks than those with earlier start dates. Unprecedented hepatitis A outbreaks were controlled by a robust vaccine response in 37 states. Continued vigilance and providing access to vaccination for recommended populations will be critical to preventing similar outbreaks in the future.
- 8 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e960-e966
Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024
Background: Hepatitis C is a public health threat with national elimination targets, yet prevalence is challenging to measure. We utilized a novel approach to estimate hepatitis C prevalence among adults using residual sera from a large commercial laboratory. Methods: We conducted a cross-sectional study in 50 states and the District of Columbia using a convenience sample of residual serum specimens (n = 81 483) among routine clinical specimens from adults aged 18–≤75 years. We randomly sampled within 2 age groups (18–≤49 years and 50–≤75 years) during November 2023–September 2024. Specimens were tested for hepatitis C virus (HCV) antibodies; reactive or equivocal results were reflexed to HCV ribonucleic acid (RNA) testing. We performed nested raking on the age–sex distribution of the United States. Results: Among adults aged 18–≤75 years, we estimated that the HCV antibody prevalence was 2.9% (95% CI, 2.8%–3.0%), corresponding to 6 887 000 (95% CI, 6 622 000–7 166 000) persons ever infected, and the HCV RNA prevalence was 0.7% (95% CI, .7%–.8%), corresponding to 1 698 000 (95% CI, 1 554 000–1 845 000) persons currently infected. Viral clearance was lower among younger adults (63.8% [95% CI, 60.6%–66.9%]) than older adults (81.1% [95% CI, 78.9%–83.3%]). Conclusions: In this analysis of residual sera from a commercial laboratory, we estimated that approximately 1.70 million adults were diagnosed with HCV infection during November 2023–September 2024. Although underlying selection bias limits generalizability to the US population, the substantial burden estimated after a decade of available curative treatment underscores the need for concerted nationwide hepatitis C elimination efforts.
- 8 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e960-e966
Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024
Background: Hepatitis C is a public health threat with national elimination targets, yet prevalence is challenging to measure. We utilized a novel approach to estimate hepatitis C prevalence among adults using residual sera from a large commercial laboratory. Methods: We conducted a cross-sectional study in 50 states and the District of Columbia using a convenience sample of residual serum specimens (n = 81 483) among routine clinical specimens from adults aged 18–≤75 years. We randomly sampled within 2 age groups (18–≤49 years and 50–≤75 years) during November 2023–September 2024. Specimens were tested for hepatitis C virus (HCV) antibodies; reactive or equivocal results were reflexed to HCV ribonucleic acid (RNA) testing. We performed nested raking on the age–sex distribution of the United States. Results: Among adults aged 18–≤75 years, we estimated that the HCV antibody prevalence was 2.9% (95% CI, 2.8%–3.0%), corresponding to 6 887 000 (95% CI, 6 622 000–7 166 000) persons ever infected, and the HCV RNA prevalence was 0.7% (95% CI, .7%–.8%), corresponding to 1 698 000 (95% CI, 1 554 000–1 845 000) persons currently infected. Viral clearance was lower among younger adults (63.8% [95% CI, 60.6%–66.9%]) than older adults (81.1% [95% CI, 78.9%–83.3%]). Conclusions: In this analysis of residual sera from a commercial laboratory, we estimated that approximately 1.70 million adults were diagnosed with HCV infection during November 2023–September 2024. Although underlying selection bias limits generalizability to the US population, the substantial burden estimated after a decade of available curative treatment underscores the need for concerted nationwide hepatitis C elimination efforts.
- 3 January 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (2) , e70123
Characteristics of Newly Reported Chronic Hepatitis C Cases Among Adults in the United States, 2016–2023: Insights From Population‐Based Surveillance
Chronic hepatitis C (CHC) continues to be a significant public health issue in the United States, but comprehensive analysis of its epidemiological characteristics is limited. This analysis used data from the National Notifiable Diseases Surveillance System to examine patterns and changes in newly reported CHC. During 2016–2023, 895,522 CHC cases were newly reported among adults aged ≥ 18 years in the United States. The rate of newly reported cases during 2020–2023 was significantly lower (47.8 cases per 100,000), compared with the rate during 2016–2019 (75.8 cases per 100,000). A distinct bimodal age distribution was observed with age peaks centered at approximately 33.9 and 59.5 years, which corresponds to millennials (born during 1981–1996) and baby boomers (born during 1945–1965), respectively. While the bimodal age distribution persisted, over time, fewer cases contributed to the older peak relative to the younger peak. Males had a significantly higher rate of newly reported CHC than females, as did individuals residing in rural areas compared to urban areas, particularly within the younger peak. Variations in the transition from the older peak to the younger peak were observed across states during 2016–2023. These findings provide valuable insights into the evolving CHC epidemiology and the implications for the efforts to eliminate the disease.
- 3 January 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (2) , e70123
Characteristics of Newly Reported Chronic Hepatitis C Cases Among Adults in the United States, 2016–2023: Insights From Population‐Based Surveillance
Chronic hepatitis C (CHC) continues to be a significant public health issue in the United States, but comprehensive analysis of its epidemiological characteristics is limited. This analysis used data from the National Notifiable Diseases Surveillance System to examine patterns and changes in newly reported CHC. During 2016–2023, 895,522 CHC cases were newly reported among adults aged ≥ 18 years in the United States. The rate of newly reported cases during 2020–2023 was significantly lower (47.8 cases per 100,000), compared with the rate during 2016–2019 (75.8 cases per 100,000). A distinct bimodal age distribution was observed with age peaks centered at approximately 33.9 and 59.5 years, which corresponds to millennials (born during 1981–1996) and baby boomers (born during 1945–1965), respectively. While the bimodal age distribution persisted, over time, fewer cases contributed to the older peak relative to the younger peak. Males had a significantly higher rate of newly reported CHC than females, as did individuals residing in rural areas compared to urban areas, particularly within the younger peak. Variations in the transition from the older peak to the younger peak were observed across states during 2016–2023. These findings provide valuable insights into the evolving CHC epidemiology and the implications for the efforts to eliminate the disease.
- 3 September 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (12) , 783-794
Evolving Characteristics of Decedents With Hepatitis A Listed as a Cause of Death, United States, 2011–2021
Hepatitis A is a vaccine‐preventable disease that typically causes mild illness. Hepatitis A outbreaks associated with person‐to‐person transmission have been widespread in the United States since 2016. We used public‐use US Multiple Cause of Death data to compare characteristics and listed comorbidities among decedents with hepatitis A‐listed deaths during non‐outbreak (2011–2015) and outbreak (2017–2021) periods and assessed the median age at death among decedents with and without hepatitis A‐listed deaths during the outbreak period. From the non‐outbreak period to the outbreak period, hepatitis A‐listed deaths more than doubled (from 369 to 801), while the hepatitis A‐listed age‐adjusted mortality rate increased 150% (p < 0.001). When compared with the non‐outbreak period, hepatitis A‐listed decedents during the outbreak period were more frequently male, aged 18–49 years, non‐Hispanic White, died in an inpatient setting, and had hepatitis A listed as their underlying cause of death. The median age at death for hepatitis A‐listed decedents was significantly younger during the outbreak period overall and among females (62 and 66 years, respectively) compared with the non‐outbreak period (64 and 72 years, respectively, p < 0.001). During the outbreak period, median age at death for hepatitis A‐listed decedents was 14 years younger than decedents without hepatitis A listed. Compared with the general US population, decedents with hepatitis A listed on the death certificate died at younger ages during 2017–2021. Efforts are needed to improve hepatitis A vaccination coverage among adults recommended for hepatitis A vaccination to prevent additional premature hepatitis A deaths.
- 3 September 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (12) , 783-794
Evolving Characteristics of Decedents With Hepatitis A Listed as a Cause of Death, United States, 2011–2021
Hepatitis A is a vaccine‐preventable disease that typically causes mild illness. Hepatitis A outbreaks associated with person‐to‐person transmission have been widespread in the United States since 2016. We used public‐use US Multiple Cause of Death data to compare characteristics and listed comorbidities among decedents with hepatitis A‐listed deaths during non‐outbreak (2011–2015) and outbreak (2017–2021) periods and assessed the median age at death among decedents with and without hepatitis A‐listed deaths during the outbreak period. From the non‐outbreak period to the outbreak period, hepatitis A‐listed deaths more than doubled (from 369 to 801), while the hepatitis A‐listed age‐adjusted mortality rate increased 150% (p < 0.001). When compared with the non‐outbreak period, hepatitis A‐listed decedents during the outbreak period were more frequently male, aged 18–49 years, non‐Hispanic White, died in an inpatient setting, and had hepatitis A listed as their underlying cause of death. The median age at death for hepatitis A‐listed decedents was significantly younger during the outbreak period overall and among females (62 and 66 years, respectively) compared with the non‐outbreak period (64 and 72 years, respectively, p < 0.001). During the outbreak period, median age at death for hepatitis A‐listed decedents was 14 years younger than decedents without hepatitis A listed. Compared with the general US population, decedents with hepatitis A listed on the death certificate died at younger ages during 2017–2021. Efforts are needed to improve hepatitis A vaccination coverage among adults recommended for hepatitis A vaccination to prevent additional premature hepatitis A deaths.
- 26 July 2024
- Published by SAGE Publications in Public Health Reports®
- Vol. 140 (1) , 115-124
Regional Differences in Hepatitis C–Related Hospitalization Rates, United States, 2012-2019
Objectives: In the United States, hepatitis C is the most commonly reported bloodborne infection. It is a leading cause of liver cancer and death from liver disease and imposes a substantial burden of hospitalization. We sought to describe regional differences in hepatitis C virus (HCV)–related hospitalizations during 2012 through 2019 to guide planning for hepatitis C elimination. Methods: We analyzed discharge data from the National Inpatient Sample for 2012 through 2019. We considered hospitalizations to be HCV-related if (1) hepatitis C was the primary diagnosis or (2) hepatitis C was any secondary diagnosis and the primary diagnosis was a liver disease–related condition. We analyzed demographic and clinical characteristics of HCV-related hospitalizations and modeled the annual percentage change in HCV-related hospitalization rates, nationally and according to the 9 US Census Bureau geographic divisions. Results: During 2012-2019, an estimated 553 900 HCV-related hospitalizations occurred in the United States. The highest hospitalization rate (34.7 per 100 000 population) was in the West South Central region, while the lowest (17.6 per 100 000 population) was in the West North Central region. During 2012-2019, annual hospitalization rates decreased in each region, with decreases ranging from 15.3% in the East South Central region to 48.8% in the Pacific region. By type of health insurance, Medicaid had the highest hospitalization rate nationally and in all but 1 geographic region. Conclusions: HCV-related hospitalization rates decreased nationally and in each geographic region during 2012-2019; however, decreases were not uniform. Expanded access to direct-acting antiviral treatment in early-stage hepatitis C would reduce future hospitalizations related to advanced liver disease and interrupt HCV transmission.
- 26 July 2024
- Published by SAGE Publications in Public Health Reports®
- Vol. 140 (1) , 115-124
Regional Differences in Hepatitis C–Related Hospitalization Rates, United States, 2012-2019
Objectives: In the United States, hepatitis C is the most commonly reported bloodborne infection. It is a leading cause of liver cancer and death from liver disease and imposes a substantial burden of hospitalization. We sought to describe regional differences in hepatitis C virus (HCV)–related hospitalizations during 2012 through 2019 to guide planning for hepatitis C elimination. Methods: We analyzed discharge data from the National Inpatient Sample for 2012 through 2019. We considered hospitalizations to be HCV-related if (1) hepatitis C was the primary diagnosis or (2) hepatitis C was any secondary diagnosis and the primary diagnosis was a liver disease–related condition. We analyzed demographic and clinical characteristics of HCV-related hospitalizations and modeled the annual percentage change in HCV-related hospitalization rates, nationally and according to the 9 US Census Bureau geographic divisions. Results: During 2012-2019, an estimated 553 900 HCV-related hospitalizations occurred in the United States. The highest hospitalization rate (34.7 per 100 000 population) was in the West South Central region, while the lowest (17.6 per 100 000 population) was in the West North Central region. During 2012-2019, annual hospitalization rates decreased in each region, with decreases ranging from 15.3% in the East South Central region to 48.8% in the Pacific region. By type of health insurance, Medicaid had the highest hospitalization rate nationally and in all but 1 geographic region. Conclusions: HCV-related hospitalization rates decreased nationally and in each geographic region during 2012-2019; however, decreases were not uniform. Expanded access to direct-acting antiviral treatment in early-stage hepatitis C would reduce future hospitalizations related to advanced liver disease and interrupt HCV transmission.
- 13 May 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (2) , 625-636
Estimating hepatitis C prevalence in the United States, 2017–2020
Background & Aims: The National Health and Nutrition Examination Survey (NHANES) underestimates the true prevalence of hepatitis C virus (HCV) infection. By accounting for populations inadequately represented in NHANES, we created two models to estimate the national hepatitis C prevalence among US adults during 2017–2020. Approach & Results: The first approach (NHANES+) replicated previous methodology by supplementing hepatitis C prevalence estimates among the US noninstitutionalized civilian population with a literature review and meta-analysis of hepatitis C prevalence among populations not included in the NHANES sampling frame. In the second approach (persons who inject drugs [PWID] adjustment), we developed a model to account for underrepresentation of PWID in NHANES by incorporating the estimated number of adult PWID in the United States and applying PWID-specific hepatitis C prevalence estimates. Using the NHANES+ model, we estimated HCV RNA prevalence of 1.0% (95% confidence interval [CI]: 0.5%-1.4%) among US adults in 2017-2020, corresponding to 2,463,700 (95% CI: 1,321,700-3,629,400) current HCV infections. Using the PWID adjustment model, we estimated HCV RNA prevalence of 1.6% (95% CI: 0.9%-2.2%), corresponding to 4,043,200 (95% CI: 2,401,800-5,607,100) current HCV infections. Conclusions: Despite years of an effective cure, estimated prevalence of hepatitis C in 2017–2020 remains unchanged from 2013–2016 when using comparable methodology. When accounting for increased injection drug use, estimated prevalence of hepatitis C is substantially higher than previously reported. National action is urgently needed to expand testing, increase access to treatment, and improve surveillance, especially among medically underserved populations, to support hepatitis C elimination goals. Export
- 13 May 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (2) , 625-636
Estimating hepatitis C prevalence in the United States, 2017–2020
Background & Aims: The National Health and Nutrition Examination Survey (NHANES) underestimates the true prevalence of hepatitis C virus (HCV) infection. By accounting for populations inadequately represented in NHANES, we created two models to estimate the national hepatitis C prevalence among US adults during 2017–2020. Approach & Results: The first approach (NHANES+) replicated previous methodology by supplementing hepatitis C prevalence estimates among the US noninstitutionalized civilian population with a literature review and meta-analysis of hepatitis C prevalence among populations not included in the NHANES sampling frame. In the second approach (persons who inject drugs [PWID] adjustment), we developed a model to account for underrepresentation of PWID in NHANES by incorporating the estimated number of adult PWID in the United States and applying PWID-specific hepatitis C prevalence estimates. Using the NHANES+ model, we estimated HCV RNA prevalence of 1.0% (95% confidence interval [CI]: 0.5%-1.4%) among US adults in 2017-2020, corresponding to 2,463,700 (95% CI: 1,321,700-3,629,400) current HCV infections. Using the PWID adjustment model, we estimated HCV RNA prevalence of 1.6% (95% CI: 0.9%-2.2%), corresponding to 4,043,200 (95% CI: 2,401,800-5,607,100) current HCV infections. Conclusions: Despite years of an effective cure, estimated prevalence of hepatitis C in 2017–2020 remains unchanged from 2013–2016 when using comparable methodology. When accounting for increased injection drug use, estimated prevalence of hepatitis C is substantially higher than previously reported. National action is urgently needed to expand testing, increase access to treatment, and improve surveillance, especially among medically underserved populations, to support hepatitis C elimination goals. Export
- Open Access
- 20 October 2023
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 72 (42) , 1128-1133
Preventable Deaths During Widespread Community Hepatitis A Outbreaks — United States, 2016–2022
This report describes deaths related to hepatitis A outbreaks.
- 20 October 2023
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 72 (42) , 1128-1133
Open AccessPreventable Deaths During Widespread Community Hepatitis A Outbreaks — United States, 2016–2022
This report describes deaths related to hepatitis A outbreaks.
- 22 July 2023
- Published by SAGE Publications in Public Health Reports®
Hepatitis C Virus–HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics
The overlapping epidemics of hepatitis C virus (HCV) and HIV infection stem from underlying behaviors and health disparities among disproportionately affected populations, especially people who inject drugs (PWID). Characterizing the prevalence of HCV–HIV coinfection offers improved data to address these underlying determinants of health. We performed a literature search for articles that describe US populations, were published during 2005-2021, and summarized evidence of the prevalence of HCV infection in recent HIV clusters and outbreaks among PWID. In population- and community-based studies, HCV antibody prevalence among PWID with HIV ranged from 10.7% to 71.4%, depending on the setting and study design. HCV–HIV coinfection ranged from 70% to 94% among 5 larger HIV clusters or outbreaks among PWID during 2014-2021; where characterized, HCV diagnosis preceded HIV detection by a median of 4 to 5 years. Robust modernized surveillance is needed to support and measure the progress of city, state, and national activities for ending the HIV epidemic and eliminating hepatitis C. Developing and leveraging surveillance systems can identify missed opportunities for prevention, evaluate care, and build capacity for outbreak investigation. In addition, improved data on injection drug use are crucial to inform efforts for improved HCV and HIV testing, prevention, and treatment in settings that serve PWID. By providing data in a wholistic, integrated manner, public health surveillance programs can support efforts to overcome inefficiencies of disease-specific silos, accelerate delivery of preventive and clinical services, and address the excess disease burden and health disparities associated with HCV–HIV coinfection.
- 22 July 2023
- Published by SAGE Publications in Public Health Reports®
Hepatitis C Virus–HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics
The overlapping epidemics of hepatitis C virus (HCV) and HIV infection stem from underlying behaviors and health disparities among disproportionately affected populations, especially people who inject drugs (PWID). Characterizing the prevalence of HCV–HIV coinfection offers improved data to address these underlying determinants of health. We performed a literature search for articles that describe US populations, were published during 2005-2021, and summarized evidence of the prevalence of HCV infection in recent HIV clusters and outbreaks among PWID. In population- and community-based studies, HCV antibody prevalence among PWID with HIV ranged from 10.7% to 71.4%, depending on the setting and study design. HCV–HIV coinfection ranged from 70% to 94% among 5 larger HIV clusters or outbreaks among PWID during 2014-2021; where characterized, HCV diagnosis preceded HIV detection by a median of 4 to 5 years. Robust modernized surveillance is needed to support and measure the progress of city, state, and national activities for ending the HIV epidemic and eliminating hepatitis C. Developing and leveraging surveillance systems can identify missed opportunities for prevention, evaluate care, and build capacity for outbreak investigation. In addition, improved data on injection drug use are crucial to inform efforts for improved HCV and HIV testing, prevention, and treatment in settings that serve PWID. By providing data in a wholistic, integrated manner, public health surveillance programs can support efforts to overcome inefficiencies of disease-specific silos, accelerate delivery of preventive and clinical services, and address the excess disease burden and health disparities associated with HCV–HIV coinfection.
- 21 July 2023
- Published by SAGE Publications in Public Health Reports®
Trends and Opportunities: Hepatitis A Virus Infection, Seroprevalence, and Vaccination Coverage—United States, 1976-2020
Objectives: The incidence of hepatitis A declined in the United States following the introduction of hepatitis A vaccines, before increasing in the setting of recent widespread outbreaks associated with person-to-person transmission. We describe the hepatitis A epidemiology in the United States, identify susceptible populations over time, and demonstrate the need for improved hepatitis A vaccination coverage, especially among adults at increased risk for hepatitis A. Methods: We calculated the hepatitis A incidence rates for sociodemographic characteristics and percentages for risk factors and clinical outcomes for hepatitis A cases reported to the National Notifiable Diseases Surveillance System during 1990-2020. We generated nationally representative estimates and 95% CIs of hepatitis A seroprevalence during 1976–March 2020 and self-reported hepatitis A vaccination coverage during 1999–March 2020 for the noninstitutionalized civilian US population using data from the National Health and Nutrition Examination Survey. Results: Overall, the rate per 100 000 population of reported cases of hepatitis A virus infection in the United States declined 17.3-fold, from 10.4 during 1990-1998 to 0.6 during 2007-2015, and then increased to 2.8 during 2016-2020. The overall hepatitis A seroprevalence in the United States increased from 38.2% (95% CI, 36.2%-40.1%) during 1976-1980 to 47.3% (95% CI, 45.4%-49.2%) during 2015–March 2020. The prevalence of self-reported hepatitis A vaccination coverage in the United States increased more than 2.5-fold, from 16.3% (95% CI, 15.0%-17.7%) during 1999-2006 to 41.9% (95% CI, 40.2%-43.7%) during 2015–March 2020. Conclusions: Hepatitis A epidemiology in the United States changed substantially during 1976-2020. Improved vaccination coverage, especially among adults recommended for vaccination by the Advisory Committee on Immunization Practices, is vital to stop current hepatitis A outbreaks associated with person-to-person transmission in the United States and prevent similar future recurrences.
- 21 July 2023
- Published by SAGE Publications in Public Health Reports®
Trends and Opportunities: Hepatitis A Virus Infection, Seroprevalence, and Vaccination Coverage—United States, 1976-2020
Objectives: The incidence of hepatitis A declined in the United States following the introduction of hepatitis A vaccines, before increasing in the setting of recent widespread outbreaks associated with person-to-person transmission. We describe the hepatitis A epidemiology in the United States, identify susceptible populations over time, and demonstrate the need for improved hepatitis A vaccination coverage, especially among adults at increased risk for hepatitis A. Methods: We calculated the hepatitis A incidence rates for sociodemographic characteristics and percentages for risk factors and clinical outcomes for hepatitis A cases reported to the National Notifiable Diseases Surveillance System during 1990-2020. We generated nationally representative estimates and 95% CIs of hepatitis A seroprevalence during 1976–March 2020 and self-reported hepatitis A vaccination coverage during 1999–March 2020 for the noninstitutionalized civilian US population using data from the National Health and Nutrition Examination Survey. Results: Overall, the rate per 100 000 population of reported cases of hepatitis A virus infection in the United States declined 17.3-fold, from 10.4 during 1990-1998 to 0.6 during 2007-2015, and then increased to 2.8 during 2016-2020. The overall hepatitis A seroprevalence in the United States increased from 38.2% (95% CI, 36.2%-40.1%) during 1976-1980 to 47.3% (95% CI, 45.4%-49.2%) during 2015–March 2020. The prevalence of self-reported hepatitis A vaccination coverage in the United States increased more than 2.5-fold, from 16.3% (95% CI, 15.0%-17.7%) during 1999-2006 to 41.9% (95% CI, 40.2%-43.7%) during 2015–March 2020. Conclusions: Hepatitis A epidemiology in the United States changed substantially during 1976-2020. Improved vaccination coverage, especially among adults recommended for vaccination by the Advisory Committee on Immunization Practices, is vital to stop current hepatitis A outbreaks associated with person-to-person transmission in the United States and prevent similar future recurrences.